CompletedPhase 3ACTRN12608000248369

The role of Gabapentin in the treatment of refractory chronic dry cough.

The role of Gabapentin in the treatment of refractory chronic dry cough: A randomised double-blind placebo-controlled study.

Sponsor

Hunter New England Area Health Service

Enrollment

56 participants

Start Date

Oct 15, 2008

Study Type

Interventional

Conditions

chronic cough

Summary

looking at effectiveness of treating persistent cough with a medication

Eligibility

Sex: Both males and femalesMin Age: 18 YearssMax Age: 80 Yearss

Inclusion Criteria5

Persistent non-productive cough of more than 8 weeks duration,
Male or female between ages of 18 and 80 years,
Non-smoker or ex-smoker with less than 10 pack years,
To have been well during the 4 weeks prior to study entry,
Informed consent obtained.

Exclusion Criteria9

Productive cough,
Current smoker,
Smoking history >10 pack years,
Pregnancy/breast feeding,
Other respiratory disease, eg: bronchiectasis, COPD.
Inability to attend study visits
Respiratory tract infection during month prior to randomisation
Impaired liver function at Visit 1 as shown by Aspartate aminotransferase (AST), an enzyme normally present in liver and heart cells and alanine aminotransferase (ALT). If the liver is injured, the liver cells spill the enzymes into blood, raising the enzyme levels in the blood and signaling liver damage.
Therefore, an AST, ALT, alkaline phosphatase or total bilirubin greater than 2 times the upper limit of normal will exclude a participant.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

300 mg of oral Neurontin once per day, then increased to 600mg/d for second day, then 900mg/d for third day upto maximum tolerable dose of 1800mg/day for ten weeks.